Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:alsoKnownAs |
HUTCHMED
|
| gptkbp:CEO |
Weiguo Su
|
| gptkbp:developedBy |
oncology drugs
immunology drugs |
| gptkbp:focusesOn |
immunology
oncology |
| gptkbp:foundedIn |
2000
|
| gptkbp:headquartersLocation |
gptkb:Hong_Kong
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hutchison China MediTech
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:London_Stock_Exchange
gptkb:NASDAQ |
| gptkbp:notableProduct |
gptkb:savolitinib
gptkb:fruquintinib gptkb:surufatinib |
| gptkbp:numberOfEmployees |
over 1,400
|
| gptkbp:operatesIn |
gptkb:China
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:parentCompany |
gptkb:CK_Hutchison_Holdings
|
| gptkbp:stockSymbol |
gptkb:HCM
|
| gptkbp:website |
https://www.hutch-med.com/
|
| gptkbp:bfsParent |
gptkb:Hutchison_MediPharma
gptkb:WuXi_Biologics |
| gptkbp:bfsLayer |
7
|